Literature DB >> 1988207

Urinary neopterin in patients with systemic lupus erythematosus.

L Leohirun1, P Thuvasethakul, V Sumethkul, T Pholcharoen, V Boonpucknavig.   

Abstract

Concentrations of neopterin were measured in urine specimens from 35 patients with active and eight with inactive systemic lupus erythematosus (SLE). Compared with those of apparently healthy controls, neopterin concentrations were higher in patients with active disease (P less than 0.001) and with inactive disease (P less than 0.01), those in patients with active disease being significantly higher than those in patients with inactive disease (P less than 0.001). The correlation between the neopterin concentration and evidence of disease activity was good. All of the patients with clinically active SLE had increased neopterin, but for only 37.5% (three of eight) did the neopterin concentration exceed the upper normal limit during clinical remission. The increase in neopterin concentration did not correlate with clinical courses or severity of renal function. Moreover, serial determinations of neopterin in active SLE patients showed a rapid decrease of initially high concentration, paralleling a decline of clinical activity after initiation of medical therapy. Thus, urinary neopterin may be a useful marker for monitoring disease activity in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988207

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Young Hee Rho; Joseph Solus; Paolo Raggi; Annette Oeser; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

2.  Urinary neopterin: an immune activation marker in mesangial proliferative glomerulonephritis.

Authors:  Kazuyuki Ueno; Masaki Shimizu; Tadafumi Yokoyama; Sayaka Ishikawa; Yuko Tasaki; Natsumi Inoue; Naotoshi Sugimoto; Kazuhide Ohta; Akihiro Yachie
Journal:  Clin Exp Nephrol       Date:  2014-05-25       Impact factor: 2.801

3.  Urinary neopterin in idiopathic retinal vasculitis.

Authors:  H E Palmer; G Giovannoni; M R Stanford; G R Wallace; E M Graham
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

4.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

Review 5.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

6.  Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants.

Authors:  Margaret Kosek; Rashidul Haque; Aldo Lima; Sudhir Babji; Sanjaya Shrestha; Shahida Qureshi; Samie Amidou; Estomih Mduma; Gwenyth Lee; Pablo Peñataro Yori; Richard L Guerrant; Zulfiqar Bhutta; Carl Mason; Gagandeep Kang; Mamun Kabir; Caroline Amour; Pascal Bessong; Ali Turab; Jessica Seidman; Maribel Paredes Olortegui; Josiane Quetz; Dennis Lang; Jean Gratz; Mark Miller; Michael Gottlieb
Journal:  Am J Trop Med Hyg       Date:  2012-11-26       Impact factor: 2.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.